Interview: Arvelle Aims To Be Major Player In CNS

Epilepsy Drug Cenobamate Filed in Europe

The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.

Businessman_Paperwork
Paperwork all done for cenobamate filing in Europe • Source: Shutterstock

With its new anti-epileptic drug cenobamate now under review in Europe, Arvelle Therapeutics GmbH is doing the groundwork for the commercial launch that should turn the Swiss biotech into a fully integrated pharmaceutical company.

Earlier this month, the European Medicines Agency accepted Arvelle's marketing authorization application (MAA) for cenobamate, which is licensed from South...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category